SCHEMBL30725409

SCHEMBL30725409

COC(=O)c1[nH]cc(F)c1Br

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 3/20 0.37
LMNA P02545 2/20 0.37
KDM4E B2RXH2 2/20 0.37
GAA P10253 2/20 0.37
POLB P06746 1/20 0.37
NFKB1 P19838 1/20 0.37
XDH P47989 1/20 0.37
GFER P55789 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
FUT7 Q11130 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CREBBP Q92793 1/20 0.34
MAPT P10636 2/20 0.34
ALPL P05186 2/20 0.33
NOTUM Q6P988 2/20 0.33
KDM4C Q9H3R0 1/20 0.33
BAZ2B Q9UIF8 1/20 0.33
BAZ2A Q9UIF9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16237134 0.79 NR4A2 (0.39) NR4A2LMNAKDM4EGAAPOLB
SCHEMBL21561526 0.79 TDP1 (0.38) NR4A2LMNAKDM4EGAAPOLB
SCHEMBL22095701 0.76 SLC6A3 (0.50) NR4A2LMNAMAPTALDH1A1HTT
SCHEMBL31210653 0.72 XDH (0.42) NR4A2LMNAKDM4EGAAPOLB
SCHEMBL16116224 0.70 NR4A2 (0.37) NR4A2LMNAKDM4EGAAPOLB
SCHEMBL2171883 0.70 KDM4E (0.42) NR4A2LMNAKDM4EGAAPOLB
SCHEMBL31211387 0.70 TPMT (0.39) NR4A2LMNAKDM4EGAAPOLB
SCHEMBL16236785 0.69 LMNA (0.36) NR4A2LMNAKDM4EGAAL3MBTL1
SCHEMBL24840712 0.69 CNR2 (0.43) NR4A2LMNAKDM4EGAAPOLB
SCHEMBL30590613 0.69 LMNA (0.37) NR4A2LMNAKDM4EGAAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4676931-A1 PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF BioSplice Therapeutics, Inc. (US) 2026-01-14 EP disclosed
US-20250340575-A1 4-AMINOPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF BIOSPLICE THERAPEUTICS INC (US) 2025-11-06 US disclosed
US-20250206746-A1 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF TENARX, INC. 2025-06-26 US disclosed
WO-2025137469-A1 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF BIOSPLICE THERAPEUTICS, INC. (US) 2025-06-26 WO disclosed
CN-119604506-A 4-Alkoxypyrrolo [2,1-f ] [1,2,4] triazines, preparation and use thereof 拜斯丽治疗有限公司 2025-03-11 CN disclosed
WO-2024211797-A1 PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF BIOSPLICE THERAPEUTICS, INC. (US) 2024-10-10 WO disclosed
US-20240002391-A1 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF TENARX, INC. 2024-01-04 US disclosed
WO-2023250156-A1 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF BIOSPLICE THERAPEUTICS, INC. (US) 2023-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250340575-A1 4-AMINOPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK2, DYRK1B NR4A2 671/4885LMNA 4160/4885KDM4E 1247/4885
US-20240002391-A1 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK2, DYRK1B NR4A2 1036/4885LMNA 3826/4885KDM4E 1400/4885
US-20250206746-A1 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK2, DYRK1B NR4A2 1036/4885LMNA 3826/4885KDM4E 1400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.